Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | TYMS | P04818 | 1/20 | 0.54 |
| ▸ | TK2 | O00142 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13412991 | 1.00 | TK1 (0.65) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL14286635 | 1.00 | TK1 (0.65) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL5057505 | 1.00 | TK1 (0.65) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL5057499 | 1.00 | TK1 (0.65) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL14286637 | 0.92 | TK1 (0.54) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL24638622 | 0.87 | TK1 (0.62) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL14252429 | 0.87 | TK1 (0.62) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL20456356 | 0.87 | TK1 (0.62) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL21912302 | 0.85 | TK1 (0.60) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL13403287 | 0.84 | TK1 (0.58) | TK1CYP1A2CYP3A4TSHRBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3086897-A | — | — | None | — | — | JP | disclosed |
| US-8680062-B2 | System for delivering therapeutic agents into living cells and cells nuclei | Deliversir Ltd. (IL) | 2014-03-25 | — | — | US | disclosed |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2008-01-03 | — | — | US | disclosed |
| US-20060160763-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2006-07-20 | — | — | US | disclosed |
| WO-2006010084-A2 | A SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELL NUCLEI | SEGEV LABORATORIES LIMITED (IL) | 2006-01-26 | — | — | WO | disclosed |
| EP-0135587-B2 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS | SYNGENE INC (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1040116-A4 | FUNCTIONALIZED PYRIMIDINE DERIVATIVES | SCRIPPS RESEARCH INST (US) | 2001-10-31 | — | — | EP | disclosed |
| US-6175001-B1 | DERIVATIZED AT C5 TO CONTAIN FUNCTIONAL GROUP THAT MIMICS THE PROPERTY OF NATURALLY OCCURRING AMINO ACID; FOR USE IN POLYMERASE CHAIN REACTIONS | THE SCRIPPS RESEARCH INSTITUTE | 2001-01-16 | — | — | US | disclosed |
| EP-1040116-A1 | FUNCTIONALIZED PYRIMIDINE DERIVATIVES | The Scripps Research Institute (US) | 2000-10-04 | — | — | EP | disclosed |
| WO-2000052192-A1 | ENZYMATIC DNA MOLECULES THAT CONTAIN MODIFIED NUCLEOTIDES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000023456-A1 | FUNCTIONALIZED PYRIMIDINE DERIVATIVES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2000-04-27 | — | — | WO | disclosed |
| US-5817786-A | Single-stranded labelled oligonucleotides of preselected sequences | MOLECULAR BIOSYSTEMS, INC. (US) | 1998-10-06 | — | — | US | disclosed |
| US-5668266-A | Synthesis of single-stranded labelled oligonucleotides of preselected sequence | SYNGENE, INC. (US) | 1997-09-16 | — | — | US | disclosed |
| US-5541313-A | Single-stranded labelled oligonucleotides of preselected sequence | MOLECULAR BIOSYSTEMS, INC. (US) | 1996-07-30 | — | — | US | disclosed |
| JP-H0386897-A | COMPOUND USEFUL FOR CHEMICAL SYNTHESIS OF DETECTABLE SINGLE CHAIN OLIGONUCLEOTIDE | MOLECULAR BIOSYST INC | 1991-04-11 | — | — | JP | disclosed |
| US-4948882-A | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis | SYNGENE, INC. (US) | 1990-08-14 | — | — | US | disclosed |
| EP-0135587-B1 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS | SYNGENE, INC. (US) | 1990-05-02 | — | — | EP | disclosed |
| EP-0135587-A4 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS. | MOLECULAR BIOSYSTEMS INC (US) | 1986-04-02 | — | — | EP | disclosed |
| EP-0135587-A1 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS. | MOLECULAR BIOSYSTEMS INC (US) | 1985-04-03 | — | — | EP | disclosed |
| WO-1984003285-A1 | DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS | MOLECULAR BIOSYSTEMS INC (US) | 1984-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160763-A1 | System for delivering therapeutic agents into living cells and cells nuclei | RCC1, NUMA1, ACIN1 | TK1 17/4885CYP1A2 4664/4885CYP3A4 4440/4885 |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | RCC1, NUMA1, ACIN1 | TK1 17/4885CYP1A2 4664/4885CYP3A4 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.